Published 1 hour ago • loading... • Updated 1 hour ago
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
Summary by Globe Newswire
6 Articles
6 Articles
+4 Reposted by 4 other sources
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline - PressReach
TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing … Continue reading "ProMIS Neurosciences Li…
Coverage Details
Total News Sources6
Leaning Left3Leaning Right0Center1Last Updated75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
C 25%
Factuality
To view factuality data please Upgrade to Premium







